Senti Biosciences is trading 5.07% up now at $0.37, but no new company-specific catalyst dated August 11, 2026 was identified.
- The latest clearly documented FDA-related announcement was May 14, when Senti reported positive RMAT meeting feedback and plans for a pivotal SENTI-202 trial; it is stale rather than a confirmed explanation.
- Broader markets are mixed, so macro sentiment does not clearly explain the gain.